Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.54 USD | +12.89% | +20.67% | +3.25% |
Mar. 27 | HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating | MT |
Mar. 26 | Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.25% | 122M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- BCAB Stock
- News BioAtla, Inc.
- BioAtla Says Clinical Benefits, Safety Profile Support Further Evaluation of Potential Lung Cancer Therapy